Results 291 to 300 of about 108,133 (341)
Some of the next articles are maybe not open access.
Circulation
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery.
Jennifer Linge +2 more
semanticscholar +1 more source
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery.
Jennifer Linge +2 more
semanticscholar +1 more source
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source
Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry
Journal of Clinical PsychopharmacologyThe glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire +3 more sources
Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function
Heart, Lung and Circulation, 2021Prevention of cardiovascular events and regression of atherosclerotic changes are the primary aims of preventive cardiovascular medicine. Arterial thrombosis is caused by endothelial dysfunction, which disrupts vascular haemostasis. Glucagon-like peptide 1 (GLP-1) receptor agonists have been initially used as glucose lowering agents, but over time have
Edin Begic, Mirsada Causevic
openaire +2 more sources
Glucagon-like peptide-1 receptor agonists and the eye
Current Opinion in OphthalmologyPurpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire +2 more sources
Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
Diabetes, obesity and metabolismTo assess whether adults with diabetes on oral hypoglycaemic agents undergoing general endotracheal anaesthesia during nine common surgical procedures who are glucagon‐like peptide‐1 receptor agonist (GLP1‐RA) users, compared with non‐users, are at ...
D. Klonoff +8 more
semanticscholar +1 more source
The Journal of Headache and Pain
Background Glucagon-like peptide-1 (GLP-1) plays a crucial role in metabolic disorders by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying, thereby improving glycemic control.
Wael Halloum +3 more
semanticscholar +1 more source
Background Glucagon-like peptide-1 (GLP-1) plays a crucial role in metabolic disorders by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying, thereby improving glycemic control.
Wael Halloum +3 more
semanticscholar +1 more source
[The glucagon-like peptide-1 receptor-agonist semaglutide].
Ugeskrift for laeger, 2020Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes.
Amalie Dyhrberg, Boje +3 more
openaire +1 more source
Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists
Annals of Pharmacotherapy, 2012Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted in adults.
Kathryn M, Hurren, Nicole R, Pinelli
openaire +2 more sources
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Nature Reviews Cardiology, 2023J. Ussher, D. Drucker
semanticscholar +1 more source